Conflict of interest: A. T. has received a research grant from AstraZeneca R&D. B. F and K. M. H. are employed at the Epidemiology Department, AstraZeneca R&D. S. Å has no conflict of interest in relation to this study.

Funding: Riks-Stroke, the Swedish Stroke Register, is funded by the National Board of Health and Welfare and the Swedish Association of Local Authorities and Regions. S. Å. has received a research scholarship from Stroke-Riksförbundet (the National Association for Stroke Patients in Sweden).

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

Background

In randomized controlled trials of secondary prevention after stroke, the risk of hemorrhage varies between 1% and 5% per year in patients with antithrombotic therapy, i.e. anticoagulants and antiplatelets.

Aim

To explore the rate and the risk of hemorrhage after stroke in a nationwide cohort.

Methods

We identified 58 868 first ever ischemic stroke patients in the Swedish Stroke Register during 2001 to 2005 (=index stroke) and followed them by record linkage to the National Patient Register. Rates of hemorrhage and hazard ratios, for comparisons of rates between subgroups, were calculated.

Results

Of the 58 586 ischemic stroke patients identified, 5527 (9·4%) had a history of hemorrhage. During follow-up (mean 2·0 years), 2876 patients endured a hemorrhage, giving an average hemorrhage rate of 2·6 (95% confidence interval 2·5–2·7) per 100 person-years. After index stroke, 11% of the patients were discharged with anticoagulants, and 79% with antiplatelets. Given the differences in baseline characteristics, the hemorrhage rates (per 100 person-years) were 2·5 (95% confidence interval 2·2–2·8), 2·4 (95% confidence interval 2·3–2·5), and 3·8 (95% confidence interval 3·5–4·2) in patients prescribed anticoagulants, antiplatelets, and no antithrombotics, respectively. There was an increased risk of hemorrhage in patients ≥75 years compared with those <75 years (hazard ratio = 1·61, 95% confidence interval 1·49–1·73) and in patients with previous hemorrhages compared with those without (hazard ratio = 1·82, 95% confidence interval 1·64–2·02).

Conclusions

When antithrombotics were used in large-scale clinical practice, the observed rates of hemorrhage were similar with anticoagulant therapy but increased with antiplatelet therapy compared with rates reported in randomized controlled trials. Old age and previous hemorrhage were associated with an increased risk of hemorrhage after an ischemic stroke.

Supporting Information

References

1 Saxena R, Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev 2004, issue 4, art. no.: CD000187.
Google Scholar
2 Algra A, De Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2006, issue 3, art. no.: CD001342.
10.1002/14651858.CD001342.pub2
Web of Science® Google Scholar
3 Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860.
10.1016/S0140-6736(09)60503-1
CAS PubMed Web of Science® Google Scholar
4 Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol 2010; 9: 273–284.
10.1016/S1474-4422(10)70038-7
CAS PubMed Web of Science® Google Scholar
5 Rother J, Crijns H. Prevention of stroke in patients with atrial fibrillation: the role of new antiarrhythmic and antithrombotic drugs. Cerebrovasc Dis 2010; 30: 314–322.
10.1159/000319608
CAS PubMed Web of Science® Google Scholar
6 European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–1262.
10.1016/0140-6736(93)92358-Z
PubMed Web of Science® Google Scholar
7 Mohr JP, Thompson JL, Lazar RM et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444–1451.
10.1056/NEJMoa011258
CAS PubMed Web of Science® Google Scholar
8 Chimowitz MI, Lynn MJ, Howlett-Smith H et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305–1316.
10.1056/NEJMoa043033
CAS PubMed Web of Science® Google Scholar
9 Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007; 6: 115–124.
10.1016/S1474-4422(06)70685-8
CAS PubMed Web of Science® Google Scholar
10 Usman MH, Notaro LA, Nagarakanti R et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol 2009; 103: 1107–1112.
10.1016/j.amjcard.2009.01.003
CAS PubMed Web of Science® Google Scholar
11 Chimowitz MI, Kokkinos J, Strong J et al. The Warfarin–Aspirin Symptomatic Intracranial Disease Study. Neurology 1995; 45: 1488–1493.
10.1212/WNL.45.8.1488
CAS PubMed Web of Science® Google Scholar
12 Evans A, Perez I, Yu G, Kalra L. Secondary stroke prevention in atrial fibrillation: lessons from clinical practice. Stroke 2000; 31: 2106–2111.
10.1161/01.STR.31.9.2106
CAS PubMed Web of Science® Google Scholar
13 Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention. A population-based study. Ann Intern Med 1999; 130: 14–22.
10.7326/0003-4819-130-1-199901050-00004
CAS PubMed Web of Science® Google Scholar
14 Torn M, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005; 165: 1527–1532.
10.1001/archinte.165.13.1527
CAS PubMed Web of Science® Google Scholar
15 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093–1100.
10.1378/chest.10-0134
PubMed Web of Science® Google Scholar
16 Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57: 173–180.
10.1016/j.jacc.2010.09.024
CAS PubMed Web of Science® Google Scholar
17 Asplund K, Hulter Asberg K, Appelros P et al. The Riks-Stroke story: building a sustainable national register for quality assessment of stroke care. Int J Stroke 2011; 6: 99–108.
10.1111/j.1747-4949.2010.00557.x
PubMed Web of Science® Google Scholar
18 Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689–2696.
10.1161/CIRCULATIONAHA.106.653048
CAS PubMed Web of Science® Google Scholar
19 Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 257S–298.
10.1378/chest.08-0674
CAS PubMed Web of Science® Google Scholar
20 Torn M, Algra A, Rosendaal FR. Oral anticoagulation for cerebral ischemia of arterial origin: high initial bleeding risk. Neurology 2001; 57: 1993–1999.
10.1212/WNL.57.11.1993
CAS PubMed Web of Science® Google Scholar
21 Burton C, Isles C, Norrie J, Hanson R, Grubb E. The safety and adequacy of antithrombotic therapy for atrial fibrillation: a regional cohort study. Br J Gen Pract 2006; 56: 697–702.
PubMed Web of Science® Google Scholar
22 Copland M, Walker ID, Tait RC. Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med 2001; 161: 2125–2128.
10.1001/archinte.161.17.2125
CAS PubMed Web of Science® Google Scholar
23 Mant J, Hobbs FD, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493–503.
10.1016/S0140-6736(07)61233-1
CAS PubMed Web of Science® Google Scholar
24 van Walraven C, Hart RG, Connolly S et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009; 40: 1410–1416.
10.1161/STROKEAHA.108.526988
CAS PubMed Web of Science® Google Scholar
25 Rothwell PM. Carotid stenting: more risky than endarterectomy and often no better than medical treatment alone. Lancet 2010; 375: 957–959.
10.1016/S0140-6736(10)60404-7
PubMed Web of Science® Google Scholar
26 Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360: 2–3.
10.1016/S0140-6736(02)09358-3
PubMed Web of Science® Google Scholar
27 Feng W, Hendry RM, Adams RJ. Risk of recurrent stroke, myocardial infarction, or death in hospitalized stroke patients. Neurology 2010; 74: 588–593.
10.1212/WNL.0b013e3181cff776
PubMed Web of Science® Google Scholar
28 Rothwell PM, Giles MF, Chandratheva A et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007; 370: 1432–1442.
10.1016/S0140-6736(07)61448-2
PubMed Web of Science® Google Scholar
29 Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant–antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004; 35: 2362–2367.
10.1161/01.STR.0000141933.75462.c2
CAS PubMed Web of Science® Google Scholar
30 Go AS, Hylek EM, Chang Y et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685–2692.
10.1001/jama.290.20.2685
CAS PubMed Web of Science® Google Scholar
31 Glader EL, Sjolander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 2010; 41: 397–401.
10.1161/STROKEAHA.109.566950
PubMed Web of Science® Google Scholar

Citing Literature

Volume8, Issue2

February 2013

Pages 80-86

Hemorrhage after ischemic stroke – relation to age and previous hemorrhage in a nationwide cohort of 58 868 patients

Abstract

Background

Aim

Methods

Results

Conclusions

Supporting Information

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Hemorrhage after ischemic stroke – relation to age and previous hemorrhage in a nationwide cohort of 58 868 patients

Abstract

Background

Aim

Methods

Results

Conclusions

Supporting Information

References

Citing Literature

References

Related

Information